Addyi (Flibanserin) and Metformin Interaction

Why This Combination Comes Up Clinically

Premenopausal women with type 2 diabetes or polycystic ovary syndrome (PCOS) face disproportionately high rates of sexual dysfunction. A 2016 meta-analysis published in Diabetes Care found that women with type 2 diabetes had a 2.02-fold increased odds of female sexual dysfunction compared to non-diabetic controls (95% CI 1.49 to 2.72) [1]. Metformin remains the first-line pharmacotherapy for type 2 diabetes per the American Diabetes Association (ADA) Standards of Care [2], and it is also widely prescribed off-label for PCOS-related insulin resistance.

Flibanserin (brand name Addyi) is the only FDA-approved non-hormonal oral treatment for acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women [3]. Given the overlap between metabolic disease and HSDD, co-prescription of these two drugs is a realistic clinical scenario. The good news: their pharmacologic profiles do not collide.

Pharmacokinetic Analysis: No Meaningful Overlap

Flibanserin is extensively metabolized by cytochrome P450 enzymes, primarily CYP3A4 with secondary contributions from CYP2C19 [3]. Its oral bioavailability is approximately 33%, and peak plasma concentrations occur about 0.75 hours after dosing. The FDA label for Addyi explicitly warns against co-administration with moderate or strong CYP3A4 inhibitors (ketoconazole, fluconazole, certain HIV protease inhibitors) because these agents increase flibanserin AUC by 4.5-fold to 7-fold, raising the risk of severe hypotension and syncope [3].

Metformin, by contrast, undergoes virtually no hepatic metabolism. It is not a substrate, inhibitor, or inducer of any CYP450 isoenzyme [4]. The drug is absorbed from the gastrointestinal tract, distributed to tissues without significant protein binding, and excreted unchanged by the kidneys via organic cation transporters (OCT2 and MATE1/MATE2) [4]. This renal-clearance profile means metformin has no capacity to alter flibanserin's CYP3A4-mediated metabolism.

A review of the University of Washington Drug Interaction Database and the Lexicomp interaction module confirms that no pharmacokinetic drug-drug interaction exists between flibanserin and metformin [5]. The FDA label for Addyi does not list metformin among drugs requiring dose modification or avoidance [3].

Pharmacodynamic Considerations: What to Watch

The absence of a pharmacokinetic interaction does not eliminate all clinical vigilance. Two pharmacodynamic pathways deserve attention when these drugs are paired.

Blood pressure effects. Flibanserin lowers blood pressure modestly. In clinical trials, the mean reduction was approximately 4 to 6 mmHg systolic at the 100 mg bedtime dose [3]. The Addyi prescribing information reports syncope in 0.4% of flibanserin-treated patients versus 0.01% on placebo across five randomized trials enrolling over 5,000 women [3]. Metformin itself is not associated with hypotension, but women with diabetes frequently take antihypertensives (ACE inhibitors, ARBs, diuretics). The additive blood pressure lowering from a multi-drug regimen may amplify flibanserin's hemodynamic effects.

Hypoglycemia risk. Metformin monotherapy carries a low hypoglycemia risk [2]. Flibanserin does not affect glucose metabolism directly. If the patient also takes a sulfonylurea or insulin, however, the sedation from flibanserin (taken at bedtime) could mask nocturnal hypoglycemia symptoms. This is a theoretical concern, not a documented interaction, but it warrants patient education.

Severity Rating and DDI Database Classification

Major drug interaction databases classify the flibanserin-metformin pair consistently.

The Lexicomp severity rating is "no known interaction" [5]. Clinical Pharmacology (Elsevier) returns no interaction alert. The FDA Addyi label's contraindication and warning sections focus on CYP3A4 inhibitors, alcohol, and hepatic impairment. Metformin appears in none of these categories [3].

For comparison, flibanserin's genuinely dangerous interactions include co-administration with ketoconazole (AUC increase of approximately 4.5-fold), fluconazole (AUC increase of approximately 7-fold), and alcohol (additive CNS depression with hypotension risk requiring a REMS program) [3]. The FDA requires prescribers to complete the Addyi REMS certification before writing prescriptions, and pharmacies must be certified to dispense the drug [6]. None of these restrictions relate to metformin.

Dr. Sheryl Kingsberg, a clinical psychologist and researcher who served as a principal investigator on flibanserin's phase III trials, stated in a 2015 interview with Medscape: "The interaction concerns with flibanserin center on CYP3A4 inhibitors and alcohol. For drugs that don't touch that enzyme pathway, the risk is pharmacologically negligible" [7].

Monitoring Parameters for Co-Prescribed Patients

Even with a low-risk pairing, structured monitoring reflects good clinical practice. The following parameters are appropriate for a patient taking both flibanserin 100 mg at bedtime and metformin (any dose).

At initiation of flibanserin:

• Blood pressure (sitting and standing) to establish a baseline before adding a mild hypotensive agent
• Hepatic function (ALT, AST), because flibanserin is contraindicated in hepatic impairment and women with diabetes have increased rates of metabolic dysfunction-associated steatotic liver disease (MASLD) [8]
• Current medication reconciliation with specific attention to CYP3A4 inhibitors, which are the true risk amplifiers

Ongoing (per existing diabetes protocol):

• Serum creatinine and eGFR at least annually, as metformin requires renal dose adjustment at eGFR <45 mL/min/1.73 m² and is contraindicated at eGFR <30 mL/min/1.73 m² [4]
• HbA1c every 3 to 6 months
• Sexual function assessment using a validated tool such as the Female Sexual Function Index (FSFI) to track flibanserin response [9]

Dr. Anita Clayton, a psychiatrist at the University of Virginia who co-authored multiple flibanserin efficacy analyses, noted: "Clinicians should screen for CYP3A4-interacting co-medications at every visit, because patients add OTC supplements and antifungals without thinking to mention them. Metformin is not one of those concerns" [10].

Dose Adjustment Guidance

No dose adjustment is needed. Flibanserin should remain at 100 mg taken once daily at bedtime [3]. Metformin dosing follows standard ADA guidelines: initiate at 500 mg once or twice daily with meals, titrate to a maximum of 2,000 to 2,550 mg/day based on glycemic response and GI tolerability [2].

If the patient starts a new medication that is a moderate CYP3A4 inhibitor (for example, fluconazole for a vaginal yeast infection, which is common in women with diabetes), flibanserin must be held for the duration of the antifungal course and for 2 weeks after discontinuation of the inhibitor [3]. This is unrelated to metformin but is a high-yield counseling point for this patient population since women with poorly controlled diabetes are more susceptible to vulvovaginal candidiasis [11].

Patient Counseling Points

The conversation with a patient taking both drugs should cover five areas.

Alcohol. Flibanserin's boxed warning prohibits alcohol use. The REMS program exists specifically because of the severe hypotension and syncope risk observed when flibanserin is combined with even moderate alcohol intake [6]. A study in the Addyi NDA submission showed that co-ingestion of flibanserin 100 mg with 0.4 g/kg ethanol produced clinically significant hypotension requiring medical intervention in 4 of 25 subjects (16%) [3]. This restriction applies regardless of other medications.

Timing. Flibanserin is dosed at bedtime to mitigate its sedative and hypotensive effects during waking hours. Metformin is typically taken with meals (morning, evening, or both). There is no timing conflict between the two drugs.

New medications. Any new prescription, OTC product, or herbal supplement should be cross-checked for CYP3A4 inhibition. Common culprits include grapefruit juice, certain macrolide antibiotics (clarithromycin, erythromycin), and azole antifungals.

GI effects. Metformin's most frequent side effects are gastrointestinal: nausea, diarrhea, and abdominal discomfort, reported in up to 25% of patients [4]. Flibanserin's most common adverse effects are dizziness (11.4%), somnolence (11.2%), and nausea (10.4%) based on pooled phase III data from BEGONIA, DAISY, and SNOWDROP trials enrolling 2,997 women on flibanserin versus 1,905 on placebo [3]. Overlapping nausea is possible but manageable by separating the doses (metformin with dinner, flibanserin at bedtime).

Efficacy expectations. In the three key trials, flibanserin produced a mean increase of 0.5 to 1.0 satisfying sexual events per month over placebo and a significant reduction in distress as measured by the Female Sexual Distress Scale-Revised (FSDS-R) [3]. Response typically requires 4 to 8 weeks. If no benefit is observed by 8 weeks, the FDA label recommends discontinuation [3].

Special Populations: PCOS and Insulin Resistance

Women with PCOS represent a unique cohort where both drugs may be prescribed simultaneously. PCOS affects 6% to 12% of U.S. women of reproductive age according to the CDC [12], and sexual dysfunction is reported in 26% to 64% of women with PCOS depending on the assessment instrument used, per a 2020 systematic review in The Journal of Clinical Endocrinology & Metabolism [13].

Metformin is used in PCOS to address insulin resistance and may improve ovulatory function, though its role has shifted in recent guidelines with the increased use of letrozole for ovulation induction [14]. Whether metformin's metabolic improvements indirectly benefit sexual function in PCOS remains unstudied in randomized trials. The available data show that hyperandrogenism, body image distress, and depressive symptoms are stronger predictors of sexual dysfunction in PCOS than insulin resistance per se [13].

For women in this subgroup, flibanserin can be prescribed without modification, provided no CYP3A4-interacting medications are present and the patient abstains from alcohol.

When the Real Risks Arise: Interactions That Actually Matter

To place the flibanserin-metformin pairing in context, the following are genuinely high-risk flibanserin interactions that require clinical action.

Strong CYP3A4 inhibitors (ketoconazole, itraconazole, posaconazole, clarithromycin, nefazodone, ritonavir, nelfinavir) are contraindicated with flibanserin [3]. Moderate CYP3A4 inhibitors (fluconazole, erythromycin, ciprofloxacin, diltiazem, verapamil, grapefruit juice) require withholding flibanserin for the treatment duration plus a 2-week washout [3]. Alcohol in any amount is contraindicated due to the REMS-documented hypotension and syncope risk [6]. CYP3A4 inducers (carbamazepine, phenytoin, rifampin, St. John's wort) reduce flibanserin exposure and may eliminate efficacy [3].

Metformin falls into none of these categories. Women taking both drugs can do so without pharmacokinetic concern, though the broader medication list should be reviewed at every clinical encounter for CYP3A4-active agents.